Status:
TERMINATED
A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma
Lead Sponsor:
Angimmune LLC
Collaborating Sponsors:
University of Louisville
Conditions:
Melanoma
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this trial is to study A-dmDT390-bisFv(UCHT1) in combination with ionizing irradiation for the treatment of stage IV melanoma, a disease that is essentially incurable with median overal...
Detailed Description
A-dmDT390-bisFv(UCHT1) (Resimmune™), an anti-T cell immunotoxin is currently being studied as a treatment for cutaneous T cell lymphoma and other CD3+ malignant diseases (FDA IND Number: 100712, Scott...
Eligibility Criteria
Inclusion
- All patients must have histologically proven stage IV metastatic melanoma consisting of at least two lesions
- Patients must have a performance status of \< 2 on Eastern Cooperative Oncology Group scale (see Appendix).
- Patients must have bilirubin \< 1.5 mg/dL, transaminases \< 2.5 X ULN, albumin \> 3 gm/dL, creatinine \< 2.0 mg/dL, adequate pulmonary function by physical exam and pulse oximetry and adequate cardiac reserve (EF \> 50% normal). Patients must have a normal echocardiogram without any evidence of cardiac chamber hypertrophy, dilatation or hypokinesis.
- Patients must give written informed consent prior to registration.
- Females and males must be willing to use an approved form of birth control while on this study and for 2 weeks after completion.
- Patients of ages 18-80 are eligible provided they have stage IV melanoma and are negative for BRAF or have failed BRAF inhibitor treatment or if they have failed or are intolerant to other established therapy known to provide clinical benefit for their condition or if they have been adequately consented and agreed to forgo FDA approved clinically meaningful therapy
Exclusion
- Inability to give informed consent because of psychiatric problems, or complicated medical problems.
- Serious concurrent medical problems, uncontrolled infections, or disseminated intravascular coagulopathy (DIC).
- Preexisting cardiovascular disease, the only exception being well controlled essential hypertension with a sitting blood pressure of \<155 systolic and \<90 diastolic without any evidence of structural heart disease or one episode of myocardial infarction \> 8 months ago. A past history of the any of the following are exclusions: congestive heart failure, atrial fibrillation, pulmonary hypertension, anticoagulant drug therapy, thromboembolic events, cardiomyopathy or a myocardial infarction within the past 8 months.
- Pregnant or nursing women will be excluded from study.
- History of congestive heart failure.
- History of cirrhosis of the liver
Key Trial Info
Start Date :
February 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT01888081
Start Date
February 1 2014
Last Update
November 23 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
James Graham Brown Cancer Center
Louisville, Kentucky, United States, 40202